ARTICLE | Financial News
EpimAb raises $25M in series A
April 25, 2017 4:33 AM UTC
EpimAb Biotherapeutics Inc. (Shanghai, China) raised $25 million in a series A round led by Oriza Seed Capital. Also participating were Decheng Capital, 3E Bioventures Capital and Trend Investment Group.
EpimAb is developing bispecific antibodies for immuno-oncology using its Fabs-In-Tandem Immunoglobulin (FIT-Ig) technology. The antibodies are designed to be more potent and stable, less immunogenic and easier to manufacture than those made by competing platforms (see BioCentury, Feb. 3). ...
BCIQ Company Profiles